Summary of year-end report<\/p>\n
Fourth quarter (2025-04-01 \u2013 2025-06-30)<\/strong><\/p>\n \u2022<\/span> Net sales amounted to SEK 0.0 million (0.0)<\/p>\n \u2022<\/span> Operating profit amounted to SEK -1.6 million (-1.6)<\/p>\n \u2022<\/span> Earnings per share* SEK -0.08 (-0.07)<\/p>\n \u2022<\/span> European patent granted for GMP manufacture of Osteodex<\/p>\n \u2022<\/span> The majority so far in the myeloma study (67%) have achieved stable disease. No significant side effects<\/p>\n <\/p>\n Full year (2024-07-01 \u2013 2025-06-30)<\/strong><\/p>\n \u2022<\/span> Net sales amounted to SEK 0.0 million (0.0)<\/p>\n \u2022<\/span> Operating profit amounted to SEK -5.3 million (-5.5)<\/p>\n \u2022<\/span> Earnings per share* SEK -0.26 (-0.25)<\/p>\n \u2022<\/span> Cash and cash equivalents at the end of the financial year amounted to SEK 14.7 (19.0) million<\/p>\n * Before and after dilution. Earnings per share: Profit for the period divided by the average number of <\/i>shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. <\/i>Amounts in brackets refer to the corresponding period last year.<\/i><\/p>\n <\/p>\n Comments from the CEO<\/strong><\/p>\n The ongoing myeloma study is being conducted at Uddevalla Hospital, PI (principal investigator) Dr Dorota Knut and at Karolinska University Hospital, Huddinge, PI Dr Katarina Uttervall dept. Hematology\/HERM. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna.<\/p>\n The primary objective is to confirm safety and tolerability and as a secondary objective to determine indications of treatment response. The patients who can be included in the study (inclusion criteria), must have relapsed\/treatment-resistant disease and received 1-5 prior lines of therapy. Treatment with ODX is given in a maximum of 7 doses, one dose every two weeks. Patients are divided into 3 dose groups, 3mg\/kg, 6mg\/kg and 9mg\/kg, 4 patients in each group. An amendment (add-on study protocol) enables follow-up of patients who responded to ODX treatment and refers to the time to new disease progression after completion of ODX treatment. No other anti-cancer treatment is given during the follow-up period.<\/p>\n Dose group 2 (6mg\/kg) is expected to be fully recruited in August\/September. Two patients in dose group 2 had progressive disease after completion of treatment. This means that so far, 67% of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). No significant, ODX-related, side effects have been noted.<\/p>\n Follow-up of all patients who had so far achieved stable disease shows that the disease-inhibiting effect lasted at most just over six months without initiation of other cancer treatment.<\/p>\n A meeting of the DMC (the independent data monitoring committee) is expected to be held in September to approve the continuation to dose group 3.<\/p>\n The results so far, i.e. for patients with relapsed\/treatment-resistant disease, must be seen as very promising.<\/p>\n Anders R Holmberg<\/i><\/p>\n